Life after ibrutinib? A new unmet need in CLL

Blood. 2015 Mar 26;125(13):2013-4. doi: 10.1182/blood-2015-02-622472.

Abstract

In this issue of Blood, Jain et al reported on the poor outcomes of patients with chronic lymphocytic leukemia (CLL) after the discontinuation of ibrutinib.

Publication types

  • Comment

MeSH terms

  • Adenine / analogs & derivatives
  • Antineoplastic Agents / therapeutic use*
  • Humans
  • Leukemia, Lymphocytic, Chronic, B-Cell / diagnosis*
  • Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
  • Piperidines
  • Pyrazoles / therapeutic use*
  • Pyrimidines / therapeutic use*
  • Withholding Treatment*

Substances

  • Antineoplastic Agents
  • Piperidines
  • Pyrazoles
  • Pyrimidines
  • ibrutinib
  • Adenine